ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2020; 11(9):2371-2381. doi:10.7150/jca.40517 This issue Cite
Research Paper
CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration
1. Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China
2. Department of Medical Research Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China
Citation:
Zhang R, Liu Q, Peng J, Wang M, Li T, Liu J, Cui M, Zhang X, Gao X, Liao Q, Zhao Y. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J Cancer 2020; 11(9):2371-2381. doi:10.7150/jca.40517. https://www.jcancer.org/v11p2371.htm
Other stylesAbstract
Background: C-X-C motif chemokine 5 (CXCL5) is an important attractant for immune cell accumulation in tumor tissues. Recent evidence has shown that CXCL5 could promote carcinogenesis and cancer progression in a variety of cancer types. However, the relationships between CXCL5, immune cell infiltration and pancreatic ductal adenocarcinoma (PDAC) remain largely unknown. This study aimed to explore the role and regulative mechanism of CXCL5 in PDAC carcinogenesis.
Materials and Methods: The expression of CXCL5 in PDAC was analyzed based on online databases and tissue microarray staining, and Western blotting of CXCL5 in PDAC cell lines and patient samples. The correlation between CXCL5 expression and clinicopathological features, prognosis and immune cell infiltration in tumor tissues was analyzed.
Results: High expression of CXCL5 was observed both in PDAC tumor tissue and PDAC cell lines, compared to normal pancreas tissues and normal ductal epithelium cells. High CXCL5 expression in tumor tissues was positively correlated with an advanced T stage (p=0.036), a positive tumor lymph node metastasis (p=0.014), a poor differentiation status (p=0.003) and a poor prognosis (p=0.001). Combination of CA242 and CXCL5 expression (p<0.0001) served as a better prognostic factor than CA242 alone (p=0.006). In addition, PDAC patients with high CXCL5 expression had more intratumoral M2 polarized macrophages (p=0.0248), neutrophils (p=0.0068) and IgG+ plasma cells (p=0.0133) than patients with low CXCL5 expression.
Conclusions: The expression of CXCL5 is elevated in pancreatic cancer cells. High CXCL5 expression is positively correlated with poor survival and the increased infiltration of several types of immune suppressive cells. Thus, CXCL5 could be a promising therapeutic target for PDAC immunotherapy.
Keywords: CXCL5, pancreatic ductal adenocarcinoma, prognosis, immune cell infiltration
Citation styles
APA
Zhang, R., Liu, Q., Peng, J., Wang, M., Li, T., Liu, J., Cui, M., Zhang, X., Gao, X., Liao, Q., Zhao, Y. (2020). CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Journal of Cancer, 11(9), 2371-2381. https://doi.org/10.7150/jca.40517.
ACS
Zhang, R.; Liu, Q.; Peng, J.; Wang, M.; Li, T.; Liu, J.; Cui, M.; Zhang, X.; Gao, X.; Liao, Q.; Zhao, Y. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J. Cancer 2020, 11 (9), 2371-2381. DOI: 10.7150/jca.40517.
NLM
Zhang R, Liu Q, Peng J, Wang M, Li T, Liu J, Cui M, Zhang X, Gao X, Liao Q, Zhao Y. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J Cancer 2020; 11(9):2371-2381. doi:10.7150/jca.40517. https://www.jcancer.org/v11p2371.htm
CSE
Zhang R, Liu Q, Peng J, Wang M, Li T, Liu J, Cui M, Zhang X, Gao X, Liao Q, Zhao Y. 2020. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J Cancer. 11(9):2371-2381.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.